SCA
VYNT

Stonebridge Capital Advisors’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Stonebridge Capital Advisors’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-133
Closed -$57K – 162
2016
Q1 		$57K Buy
+133
New +$49.8K 0.02% 148

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Stonebridge Capital Advisors's VYNT Position: Q2 2016 in Review

Stonebridge Capital Advisors sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2016, closing a stake of 133 shares — an estimated $57K sold.

Stonebridge Capital Advisors first reported a position in VYNT in Q1 2016 and held it in 1 quarter. The position peaked at $57K in Q1 2016. 33 funds tracked by Wall St. Rank hold VYNT as of Q2 2016.

  • Stonebridge Capital Advisors reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 133 Vyant Bio, Inc. Common Stock shares in Q2 2016, an estimated $57K.
  • Stonebridge Capital Advisors first reported a position in Vyant Bio, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • Stonebridge Capital Advisors's Vyant Bio, Inc. Common Stock position peaked at $57K in Q1 2016.
  • 33 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2016.

Based on Stonebridge Capital Advisors's 13F filing for Q2 2016, filed 16 Aug 2016.